Traficet-EN
GSK moves Crohn’s disease drug into phase III
January 14, 2011Research and Development ChemoCentryx, Crohn’s disease, GSK’786, GlaxoSmithKline, Traficet-EN
GlaxoSmithKline and its partner ChemoCentryx have started late-stage trials of GSK’786 for Crohn’s disease. The initial study is a randomised, …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
